ÖZİLHAN, S. Et Al. 2015. Risperidone/Paliperidone Plasma Level's Ratio Can Be Used As A Cyp2d6 Pm Phenotyping Marker. 1st Pharmacogenomics Istanbul Summit: Increasing The Safety And Effectiveness Of Personalized Therapy For Metabolic Disorders , (İstanbul, Turkey), 82.

ÖZİLHAN, S., CANBOLAT, F., KUL, A., ATİK, U., ÖZDEN, S. T., & TARHAN, K. N., (2015). Risperidone/Paliperidone Plasma Level's Ratio Can Be Used As A Cyp2d6 Pm Phenotyping Marker . 1st Pharmacogenomics Istanbul Summit: Increasing The Safety And Effectiveness Of Personalized Therapy For Metabolic Disorders (pp.82). İstanbul, Turkey

ÖZİLHAN, SELMA Et Al. "Risperidone/Paliperidone Plasma Level's Ratio Can Be Used As A Cyp2d6 Pm Phenotyping Marker," 1st Pharmacogenomics Istanbul Summit: Increasing The Safety And Effectiveness Of Personalized Therapy For Metabolic Disorders, İstanbul, Turkey, 2015

ÖZİLHAN, SELMA Et Al. "Risperidone/Paliperidone Plasma Level's Ratio Can Be Used As A Cyp2d6 Pm Phenotyping Marker." 1st Pharmacogenomics Istanbul Summit: Increasing The Safety And Effectiveness Of Personalized Therapy For Metabolic Disorders , İstanbul, Turkey, pp.82, 2015

ÖZİLHAN, S. Et Al. (2015) . "Risperidone/Paliperidone Plasma Level's Ratio Can Be Used As A Cyp2d6 Pm Phenotyping Marker." 1st Pharmacogenomics Istanbul Summit: Increasing The Safety And Effectiveness Of Personalized Therapy For Metabolic Disorders , İstanbul, Turkey, p.82.

@conferencepaper{conferencepaper, author={SELMA ÖZİLHAN Et Al. }, title={Risperidone/Paliperidone Plasma Level's Ratio Can Be Used As A Cyp2d6 Pm Phenotyping Marker}, congress name={1st Pharmacogenomics Istanbul Summit: Increasing The Safety And Effectiveness Of Personalized Therapy For Metabolic Disorders}, city={İstanbul}, country={Turkey}, year={2015}, pages={82} }